Canaan ADR: 5 Buys, 1 Sell, $1.92 Target vs $0.39 Price

For equity and small-cap investors, the Canaan analyst roundup is a live example of a target-price disconnect. A stock trading at $0.39 with a claimed average target of $1.92 and five buy ratings would normally scream opportunity—but the financials show a company losing money rapidly, and the target may be anchored to stale last-year coverage rather than current fundamentals.

On September 25, 2026, two syndicated market-data press releases from Ticker Report and Daily Political reported that shares of Canaan Inc. Sponsored ADR (NASDAQ: CAN) carry a consensus recommendation of 'Moderate Buy' from six sell-side research firms, according to MarketBeat. The reports attribute five buy ratings and one sell rating, with an average twelve-month price target of $1.92 among brokerages that have issued coverage in the last year. The stock opened at $0.39 on the day of publication, which means that average target is a claimed 392% above the market price. This gap is the central puzzle in the data and deserves scrutiny rather than acceptance.

“

The 50-day simple moving average sits at $0.29 and the 200-day at $0.37, while the stock opened at $0.39 on September 25.

It is important to note that both source documents are press-release or newswire distributions, not independently reported articles. They repackage MarketBeat's aggregation without original reporting, so the ratings, target price, and ownership data should be treated as reported claims from a data aggregator and the underlying brokerage notes, rather than as independently confirmed developments. The underlying financials, however, provide concrete context for evaluating those claims.

Canaan is a fabless semiconductor company best known for designing ASIC chips used in Bitcoin mining hardware. That single fact explains many of the stock's unusual characteristics. The beta of 2.72 implies that CAN shares have historically moved with roughly 2.7 times the volatility of the broad market, and the 52-week range of $0.15 to $2.22 confirms that the equity behaves more like a leveraged crypto-mining derivative than a stable semiconductor name. That context matters when reading the Moderate Buy headline.

The most recent earnings disclosure, dated August 15, 2026, reported a loss of $0.14 per share on revenue of $31.86 million. The company's net margin was negative 67.78%, and return on equity was negative 77.73%. These are not healthy profitability metrics. A price-to-earnings ratio of -0.89 simply reflects negative trailing earnings and carries little informational value beyond confirming losses. At the same time, the balance sheet is not distressed in the short term: the current ratio of 2.86, quick ratio of 1.67, and debt-to-equity ratio of 0.12 suggest Canaan can meet near-term obligations without excessive leverage.

The rating distribution helps explain why the consensus is Moderate Buy rather than Strong Buy. Five analysts rate the stock a buy, but Weiss Ratings reissued a sell (e+) recommendation on August 14, 2026. Rosenblatt Securities restated its buy rating and set a $0.75 price objective on September 15, 2026. That $0.75 target is far below the $1.92 average, which likely includes one or more stale targets from earlier in the last year. Investors should be cautious when using the $1.92 figure as a forward-looking consensus; it is an arithmetic artifact of coverage history and the six ratings, not necessarily a clear current view.

Institutional ownership data adds another layer. The reports state that institutional investors and hedge funds own 70.14% of the stock. SG Americas Securities LLC disclosed a new position of 100,000 shares in the first quarter, valued at approximately $43,000. That is a small stake by institutional standards, and the disclosure timing suggests the valuation was based on a price around $0.43 per share. The high institutional ownership percentage could also reflect passive or index holdings rather than active conviction, and the new hedge-fund position is not large enough to anchor a thesis.